Aminobutyric Acid in Rat Brain Tissue Samples Using Benzoyl Chloride Derivatization and PDA Detection

• Autorzy: Akula K. K. , Chandrasekaran B. , Kaur M. , Kulkarni S. K.
• Języki publikacji: EN

Abstrakty

EN

A new, rapid, and specific reversed phase high-performance liquid chromatographic (RP-HPLC) method involving precolumn derivatization with benzoyl chloride was developed and validated for the estimation of γ-aminobutyric acid (GABA) in rat brain tissue preparations. The derivatization product of GABA was identified by melting point, infrared, and proton nuclear magnetic resonance (1H NMR) spectroscopy to be n-benzoyl GABA. Various parameters which influenced derivatization and elusion were optimized. The chromatographic system consisted of C-18 column with ultraviolet (UV)—photodiode array detection ranging from 210 to 400 nm. Elution with an isocratic mobile phase consisting of 0.025 M disodium hydrogen phosphate buffer—methanol (65:35, v/v; pH 6) at a flow rate of 1 mL min^-1 yielded sharp and specific peak of n-benzoyl GABA within 7 min. The method was validated with respect to the linearity, accuracy, precision, sensitivity, selectivity, and stability, wherein the benzoyl derivative of GABA showed stability for 2 months. The lower limit of detection was 0.5 nmol L^-1. This novel derivatization procedure for the estimation of GABA with benzoyl chloride was also applied for rat brain tissue preparations that gave highly specific peak and good component recovery. The results show that the method for the determination of GABA by benzoylation using RP-HPLC has good linearity, accuracy, precision, sensitivity, and specificity and is simple and economical to perform.

Słowa kluczowe

EN

GABA; benzoyl chloride; RP-HPLC; PDA; brain tissue; validation

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2015
• Tom: Vol. 27, no. 3
• Strony: 413--433
• Opis fizyczny: Bibliogr. 25 poz., rys., tab.

Twórcy

autor

Akula K. K.

• RS Dow Neurobiology Laboratories, Legacy Research Institute, Portland, OR 97232, USA

autor

Chandrasekaran B.

• Centre with Potential for Excellence in Biomedical Sciences, Panjab University, Chandigarh, 160014, India

autor

Kaur M.

• Centre with Potential for Excellence in Biomedical Sciences, Panjab University, Chandigarh, 160014, India

autor

Kulkarni S. K.

• Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India

Bibliografia

• [1] S.K. Kulkarni, Developments in Psychopharmacology, vol. 1, Satish Serial Publishing House, New Delhi, India, 2006, pp. 1–13
• [2] B. George and S.K. Kulkarni, Methods Find. Exp. Clin. Pharmacol., 18, 335–340 (1996)
• [3] K. Rea, T.I.F.H. Cremers, and B.H.C. Westerink, J. Neurochem., 94, 672–679 (2005)
• [4] A.A. Monge-Acuña and J. Fornaguera-Trías, J. Neurosci. Methods, 183, 176–181 (2009)
• [5] B.A. Donzanti and B.K. Yamamoto, Life Sci., 43, 913–922 (1988)
• [6] S. Murai, H. Nagahama, H. Saito, H. Miyate, Y. Masuda, and T. Itoh, J. Pharmacol. Methods, 21, 115–121 (1989)
• [7] H.L. Rowley, K.F. Martin, and C.A. Marsden, J. Neurosci. Methods, 57, 93–99 (1995)
• [8] D.M. de Freitas Silva, V.P. Ferraz, and A.M. Ribeiro, J. Neurosci. Methods, 177, 289–293 (2009)
• [9] L. Bianchi, L. Della Corte, and K.F. Tipton, J. Chromatogr. B, 723, 47–59 (1999)
• [10] Y. Xiao, X.D. Yu, K. Wang, J.J. Xu, J. Huang, and H.Y. Chen, Talanta, 71, 2048–2055 (2007)
• [11] G. Clarke, S. O’Mahony, G. Malone, and T.G. Dinan, J. Neurosci. Methods, 160, 223–230 (2007)
• [12] S. Zhang, Y. Takeda, S. Hagioka, K. Takata, H. Aoe, H. Nakatsuka, M. Yokoyama, and K. Morita, Brain Res. Protoc., 14, 61–66 (2005)
• [13] J.L. Adcock, N.W. Barnett, J.W. Costin, P.S. Francis, and S.W. Lewis, Talanta, 67, 585–589 (2005)
• [14] X.E. Zhao and Y.R. Suo, Talanta, 76, 690–697 (2008)
• [15] J. Oehlke, M. Brudel, and I.E. Blasig, J. Chromatogr. B, 655, 105–111 (1994)
• [16] M. Yoshitake, H. Nohta, H. Yoshida, T. Yoshitake, K. Todoroki, and M. Yamaguchi, Anal. Chem., 78, 920–927 (2006)
• [17] H.E. Carter and C.M. Stevens, J. Biol. Chem., 138, 627–629 (1941)
• [18] S.M. Lasley, R.D. Greenland, and I.A. Michaelson, Life Sci., 35, 1921–1930 (1984)
• [19] J. McKenzie, C. Watson, R. Rostand, I. German, S. Witowski, and R. Kennedy, J. Chromatogr. A, 962, 105–115 (2002)
• [20] US Department of Health and Humans Services, Food and Drug Administration, Guidance for Industry Q2B Validation of Analytical Procedures: Methodology, 1996, http://www.fda.gov/cber/guidelines.htm
• [21] K.K. Akula, M. Kaur, M. Bishnoi, and S.K. Kulkarni, J. Sep. Sci., 31, 3139–3147 (2008)
• [22] T.P. Piepponen and A. Skujins, J. Chromatogr. B, 757, 277–283 (2001)
• [23] A.G. Chapman, K. Riley, M.C. Evans, and B.S. Meldrum, Neurochem. Res., 7, 1089–1105 (1982)
• [24] T. de Boer, J.C. Stoof, and H. van Duijn, Brain Res., 253, 153–160 (1982)
• [25] G. Nyitrai, K.A. Kékesi, and G. Juhász, Curr. Top. Med. Chem., 6, 935–940 (2006